DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its subsidiary, DNAPrint Pharmaceuticals, Inc., has completed the development of the so-called "Western blot" method, an analytical procedure that identifies a protein according to its interaction with a specific antibody, a significant step in the development of its PT-401-based proprietary drug to treat anemia.
